Grünenthal is a science-based, privately-owned pharmaceutical company focused on pain management and related diseases.

Grünenthal

Fresenius Kabi specializes in lifesaving medicines and technologies for critically and chronically ill patients and focuses on improving healthcare results. The company is involved in the fields of Pharma, Nutrition, MedTech, and Biopharma.

Fresenius Kabi

Körber is an international technology group that focuses on transforming entrepreneurial thinking into customer success and shaping technological change. The company employs over 12,000 people at more than 100 locations worldwide.

Körber

MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and electronics sectors worldwide. It discovers, develops, manufactures, and markets pharmaceutical and biological prescription drugs to treat neurology and immunology, oncology, fertility, and cardiology metabolism and endocrinology. The company also supplies products, tools, and services for research laboratories, pharma and biotech production, and industrial and testing laboratories. In addition, it offers material for integrated circuits, liquid crystals, organic light-emitting diodes, photoresists, smart antenna, and liquid crystal glazing solutions, as well as effect pigments for use in automotive coatings, cosmetics, industrial, and plastic applications. It has strategic alliances with Pfizer Inc.; agreement with Novartis AG; and license agreements with Debiopharm International SA and MoonLake Immunotherapeutics AG. The company was founded in 1668 and is headquartered in Darmstadt, Germany. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kommanditgesellschaft.

Metric
Company Name	Grünenthal	Fresenius Kabi	Körber	MERCK Kommanditgesellschaft auf Aktien
Symbol				MRK
MSH ID	COM:GRUNENTHAL	COM:FRESENIUS-KABI	COM:KOERBER	COM:MERCKGROUP
Market	PRIVATE	PRIVATE	PRIVATE	STOCKS
Sector	Healthcare & Health Services	Healthcare & Health Services	Technology	Healthcare
Industry	Pharmaceuticals	Pharmaceuticals	Technology and Engineering	Drug Manufacturers - Specialty & Generic
Country	DE	DE	DE	DE
Stage
Employee Count		10.00K		62.34K
Website	grunenthal.com	fresenius-kabi.com	koerber.com	merckgroup.com
LinkedIn			k%C3%B6rber
Founders

Metric
Market Cap				68.68B
Enterprise Value
Monthly Web Traffic				1.20M
Web Traffic Growth				0.02
Valuation
Raised Capital				2.77M

Metric
Revenue				22.17B
Revenue (LTM)
Revenue (NTM)
Gross Profit				12.33B
EBITDA				6.15B
Operating Income				4.27B
Net Income				2.98B
EPS				6.87
Diluted EPS				6.87
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin				0.59
Operating Profit Margin				0.19
EBITDA Margin				0.28
Net Profit Margin				0.13
Return on Equity				0.10
Return on Assets				0.06
Return on Capital Employed				0.10

COM:GRUNENTHAL

Grünenthal

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio				22.33
P/B Ratio				2.29
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio				3.64
EV Multiple				11.50

Metric
Days Sales Outstanding				82.97
Days Payables Outstanding				95.71
Days Inventory Outstanding				197.34
Operating Cycle				282.62
Cash Conversion Cycle				193.24
Asset Turnover				0.43

Metric
Operating Cash Flow				4.00B
Free Cash Flow				-774.22M
Cash Flow to Debt				0.41
Operating Cash Flow/Sales				0.20
Free Cash Flow Yield				0.03

Metric
Cash & Equivalents				2.09B
Accounts Receivable				-8.45M
Inventory				4.90B
Goodwill				18.85B
Debt to Capitalization				0.26
Debt to Assets				0.22
Current Ratio				1.56
Quick Ratio				0.84

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue				0.12
SG&A to Revenue				0.06